Patients using the eczema biologic Ebglyss have a dosing option that cuts the minimum number of injections in half, though it applies only after a months-long starting course.
FDA approved a regimen of one maintenance dose every eight weeks of a single 250 mg injection of Ebglyss, generic name lebrikizumab-lbkz, on June 9. It covers adults and children 12 and older who weigh at least 40 kg, or about 88 pounds, with moderate-to-severe atopic dermatitis not adequately controlled by topical prescription therapies. The drug was already approved for once-monthly maintenance dosing. The label change means as few as six maintenance injections per year rather than twelve, and it does so without requiring a concurrent prescription topical.
